Lucid Scientific is a technology company.
Lucid Scientific has raised $3.0M across 1 funding round.
Lucid Scientific has raised $3.0M in total across 1 funding round.
Lucid Scientific has raised $3.0M in total across 1 funding round.
Lucid Scientific's investors include Dynamk Capital.
Lucid Scientific is a biotechnology tools company founded in 2012 that develops innovative systems for monitoring cell culture experiments to accelerate drug discovery and basic biological research.[1][2][4] Its flagship product, RESIPHER, is a non-invasive sensor integrated into a sterilized lid for standard 96-well plates, enabling continuous, real-time measurement of oxygen consumption streamed to a web app, serving lab researchers studying cell growth, dose response, and cell line development.[1][3] RESIPHER's sensors are 10 times smaller and more sensitive than competitors, supporting monitoring for up to four weeks with easy setup, addressing limitations of conventional methods by providing precise, quantitative data on cellular metabolism without disrupting experiments.[1][3]
The company targets academic and industry researchers, solving the problem of indirect, endpoint-based cell analysis by offering live, dynamic insights that improve experimental accuracy and efficiency.[1][4] Currently in an early-access program with top researchers, Lucid demonstrates growth momentum through partnerships and validation against traditional techniques.[1]
Lucid Scientific was established in 2012 in Atlanta, GA, emerging from the need to modernize cell biology research tools.[2][3] Led by Walker Inman as CEO, the company has focused on biotechnology innovations from its base at Georgia Tech's vicinity (311 Ferst Drive) and additional Atlanta addresses.[1][2][3] The core idea for RESIPHER stemmed from recognizing gaps in real-time oxygen monitoring for cell cultures, aiming to "reshape the future of cell culture" by redefining traditional approaches with continuous, non-invasive analysis.[2] Early traction includes developing proprietary sensors and launching an early-access program to demonstrate benefits over conventional methods, humanizing its mission through direct collaboration with researchers.[1]
Lucid Scientific rides the trend of real-time biomanufacturing and precision cell biology tools, where demand for non-invasive monitoring aligns with advances in drug discovery and personalized medicine.[4] Timing is ideal amid rising investments in biotech automation post-2020s lab digitization waves, as market forces like high-throughput screening needs and AI-driven data analysis favor scalable, sensitive sensors over labor-intensive methods.[1][4] By streaming metabolic data to web apps, Lucid influences the ecosystem, empowering researchers at Georgia Research Alliance hubs and beyond to iterate faster, potentially reducing drug development timelines and costs in a $100B+ cell culture market.[1]
Lucid Scientific is poised for expansion beyond early access, likely scaling RESIPHER commercialization through pharma partnerships and broader plate compatibility.[1] Trends like AI integration for predictive modeling and multi-omic sensors will shape its path, amplifying influence in automated labs. As biotech shifts to continuous data paradigms, Lucid could redefine cell culture standards, evolving from innovator to essential platform in research workflows—building on its mission to reshape biology one precise measurement at a time.[2]
Lucid Scientific has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in September 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2020 | $3.0M Seed | Dynamk Capital |